The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model

Meng Yang, Doug W. Burton, Jack Geller, Darren J. Hillegonds, Randolph H. Hastings, Leonard J. Deftos, Robert M. Hoffman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Metastatic bone disease is one of the major causes of morbidity and mortality in prostate cancer patients. Bisphosphonates are currently used to inhibit bone resorption and reduce tumor-induced skeletal complications. More effective bisphosphonates would enhance their clinical value. Experimental Design: We tested several bisphosphonates in a green fluorescent protein (GFP) - expressing human prostate cancer nude mouse model. The in vivo effects of four bisphosphonates, including pamidronate, etidronic acid, and olpadronate, on bone tumor burden in mice intratibially inoculated with PC-3-GFP human prostate cancer cells were visualized by whole-body fluorescence imaging and X-ray. Results: The PC-3-GFP cells produced extensive bone lesions when injected into the tibia of immunocompromised mice. The skeletal progression of the PC-3-GFP cell growth was monitored by GFP fluorescence and the bone destruction was evaluated by X-ray. We showed that 3,3-dimethylaminopropane-1-hydroxy-1,1- diphosphonic acid (olpadronate) was the most effective bisphosphonate treatment in reducing tumor burden as assessed by GFP imaging and radiography. The GFP tumor area and X-ray score significantly correlated. Reduced tumor growth in the bone was accompanied by reduced serum calcium, parathyroid hormone - related protein, and osteoprotegerin. Conclusions: The serum calcium, parathyroid hormone - related protein, and osteoprotegerin levels were significantly correlated with GFP area and X-ray scores. Treatment with olpadronate reduced tumor growth in the bone measured by GFP and X-ray imaging procedures. Imaging of GFP expression enables monitoring of tumor growth in the bone and the GFP results complement the X-ray assessment of bone disease. The data in this report suggest that olpadronate has potential as an effective inhibitor of the skeletal progression of clinical prostate cancer.

Original languageEnglish (US)
Pages (from-to)2602-2606
Number of pages5
JournalClinical Cancer Research
Volume12
Issue number8
DOIs
StatePublished - Apr 15 2006
Externally publishedYes

Fingerprint

Diphosphonates
Green Fluorescent Proteins
Nude Mice
Prostatic Neoplasms
X-Rays
Bone Development
Parathyroid Hormone-Related Protein
Osteoprotegerin
pamidronate
Bone Diseases
Neoplasms
Tumor Burden
Bone and Bones
olpadronic acid
Etidronic Acid
Calcium
Whole Body Imaging
Optical Imaging
Bone Resorption
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yang, M., Burton, D. W., Geller, J., Hillegonds, D. J., Hastings, R. H., Deftos, L. J., & Hoffman, R. M. (2006). The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clinical Cancer Research, 12(8), 2602-2606. https://doi.org/10.1158/1078-0432.CCR-05-2050

The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. / Yang, Meng; Burton, Doug W.; Geller, Jack; Hillegonds, Darren J.; Hastings, Randolph H.; Deftos, Leonard J.; Hoffman, Robert M.

In: Clinical Cancer Research, Vol. 12, No. 8, 15.04.2006, p. 2602-2606.

Research output: Contribution to journalArticle

Yang, M, Burton, DW, Geller, J, Hillegonds, DJ, Hastings, RH, Deftos, LJ & Hoffman, RM 2006, 'The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model', Clinical Cancer Research, vol. 12, no. 8, pp. 2602-2606. https://doi.org/10.1158/1078-0432.CCR-05-2050
Yang, Meng ; Burton, Doug W. ; Geller, Jack ; Hillegonds, Darren J. ; Hastings, Randolph H. ; Deftos, Leonard J. ; Hoffman, Robert M. / The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 8. pp. 2602-2606.
@article{ca6b8c6540a2471e8bbe08c7759ffbdc,
title = "The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model",
abstract = "Purpose: Metastatic bone disease is one of the major causes of morbidity and mortality in prostate cancer patients. Bisphosphonates are currently used to inhibit bone resorption and reduce tumor-induced skeletal complications. More effective bisphosphonates would enhance their clinical value. Experimental Design: We tested several bisphosphonates in a green fluorescent protein (GFP) - expressing human prostate cancer nude mouse model. The in vivo effects of four bisphosphonates, including pamidronate, etidronic acid, and olpadronate, on bone tumor burden in mice intratibially inoculated with PC-3-GFP human prostate cancer cells were visualized by whole-body fluorescence imaging and X-ray. Results: The PC-3-GFP cells produced extensive bone lesions when injected into the tibia of immunocompromised mice. The skeletal progression of the PC-3-GFP cell growth was monitored by GFP fluorescence and the bone destruction was evaluated by X-ray. We showed that 3,3-dimethylaminopropane-1-hydroxy-1,1- diphosphonic acid (olpadronate) was the most effective bisphosphonate treatment in reducing tumor burden as assessed by GFP imaging and radiography. The GFP tumor area and X-ray score significantly correlated. Reduced tumor growth in the bone was accompanied by reduced serum calcium, parathyroid hormone - related protein, and osteoprotegerin. Conclusions: The serum calcium, parathyroid hormone - related protein, and osteoprotegerin levels were significantly correlated with GFP area and X-ray scores. Treatment with olpadronate reduced tumor growth in the bone measured by GFP and X-ray imaging procedures. Imaging of GFP expression enables monitoring of tumor growth in the bone and the GFP results complement the X-ray assessment of bone disease. The data in this report suggest that olpadronate has potential as an effective inhibitor of the skeletal progression of clinical prostate cancer.",
author = "Meng Yang and Burton, {Doug W.} and Jack Geller and Hillegonds, {Darren J.} and Hastings, {Randolph H.} and Deftos, {Leonard J.} and Hoffman, {Robert M.}",
year = "2006",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-05-2050",
language = "English (US)",
volume = "12",
pages = "2602--2606",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model

AU - Yang, Meng

AU - Burton, Doug W.

AU - Geller, Jack

AU - Hillegonds, Darren J.

AU - Hastings, Randolph H.

AU - Deftos, Leonard J.

AU - Hoffman, Robert M.

PY - 2006/4/15

Y1 - 2006/4/15

N2 - Purpose: Metastatic bone disease is one of the major causes of morbidity and mortality in prostate cancer patients. Bisphosphonates are currently used to inhibit bone resorption and reduce tumor-induced skeletal complications. More effective bisphosphonates would enhance their clinical value. Experimental Design: We tested several bisphosphonates in a green fluorescent protein (GFP) - expressing human prostate cancer nude mouse model. The in vivo effects of four bisphosphonates, including pamidronate, etidronic acid, and olpadronate, on bone tumor burden in mice intratibially inoculated with PC-3-GFP human prostate cancer cells were visualized by whole-body fluorescence imaging and X-ray. Results: The PC-3-GFP cells produced extensive bone lesions when injected into the tibia of immunocompromised mice. The skeletal progression of the PC-3-GFP cell growth was monitored by GFP fluorescence and the bone destruction was evaluated by X-ray. We showed that 3,3-dimethylaminopropane-1-hydroxy-1,1- diphosphonic acid (olpadronate) was the most effective bisphosphonate treatment in reducing tumor burden as assessed by GFP imaging and radiography. The GFP tumor area and X-ray score significantly correlated. Reduced tumor growth in the bone was accompanied by reduced serum calcium, parathyroid hormone - related protein, and osteoprotegerin. Conclusions: The serum calcium, parathyroid hormone - related protein, and osteoprotegerin levels were significantly correlated with GFP area and X-ray scores. Treatment with olpadronate reduced tumor growth in the bone measured by GFP and X-ray imaging procedures. Imaging of GFP expression enables monitoring of tumor growth in the bone and the GFP results complement the X-ray assessment of bone disease. The data in this report suggest that olpadronate has potential as an effective inhibitor of the skeletal progression of clinical prostate cancer.

AB - Purpose: Metastatic bone disease is one of the major causes of morbidity and mortality in prostate cancer patients. Bisphosphonates are currently used to inhibit bone resorption and reduce tumor-induced skeletal complications. More effective bisphosphonates would enhance their clinical value. Experimental Design: We tested several bisphosphonates in a green fluorescent protein (GFP) - expressing human prostate cancer nude mouse model. The in vivo effects of four bisphosphonates, including pamidronate, etidronic acid, and olpadronate, on bone tumor burden in mice intratibially inoculated with PC-3-GFP human prostate cancer cells were visualized by whole-body fluorescence imaging and X-ray. Results: The PC-3-GFP cells produced extensive bone lesions when injected into the tibia of immunocompromised mice. The skeletal progression of the PC-3-GFP cell growth was monitored by GFP fluorescence and the bone destruction was evaluated by X-ray. We showed that 3,3-dimethylaminopropane-1-hydroxy-1,1- diphosphonic acid (olpadronate) was the most effective bisphosphonate treatment in reducing tumor burden as assessed by GFP imaging and radiography. The GFP tumor area and X-ray score significantly correlated. Reduced tumor growth in the bone was accompanied by reduced serum calcium, parathyroid hormone - related protein, and osteoprotegerin. Conclusions: The serum calcium, parathyroid hormone - related protein, and osteoprotegerin levels were significantly correlated with GFP area and X-ray scores. Treatment with olpadronate reduced tumor growth in the bone measured by GFP and X-ray imaging procedures. Imaging of GFP expression enables monitoring of tumor growth in the bone and the GFP results complement the X-ray assessment of bone disease. The data in this report suggest that olpadronate has potential as an effective inhibitor of the skeletal progression of clinical prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33646388648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646388648&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2050

DO - 10.1158/1078-0432.CCR-05-2050

M3 - Article

C2 - 16638872

AN - SCOPUS:33646388648

VL - 12

SP - 2602

EP - 2606

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -